▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / EBS

EBS — Emergent BioSolutions Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1367644 ·
Last close
$5.18
Market Cap
$265.60M
52W High
$9.40
52W Low
$4.36
ADV30
1,170,704
Next earnings
2026-10-28
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 226,800,000 129,700,000 66,200,000 -180,200,000 1,116,800,000 139,700,000 775,400,000
Mar 2026 149,700,000 77,700,000 10,500,000 6,800,000 1,320,400,000 160,300,000 797,300,000
Dec 2025 143,800,000 58,900,000 -15,700,000 -54,600,000 1,318,600,000 205,400,000 796,000,000
Sep 2025 222,000,000 136,100,000 76,500,000 51,200,000 1,461,000,000 245,500,000 878,500,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$148,000,000
Investing CF
$7,500,000
Financing CF
$-147,600,000
CapEx
$-12,600,000
Dividends Paid
—
Buybacks
$-33,900,000
EPS Diluted TTM
$-0.28
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-333,200,000
Inventory
$303,600,000
Receivables
$190,000,000
ST Investments
—
EBIT TTM
$-95,100,000
Pretax Income TTM
$-146,000,000
Interest Exp TTM
$50,900,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$770,200,000
EBITDA
$232,400,000
Free Cash Flow
$37,500,000
Enterprise Value
$708,968,576
Total Cash
$139,700,000
Total Debt
$588,200,000
Shares Out
51,273,336
Trailing EPS
$-3.41
Book Value
$6.66
ROE
-40.3%
ROA
6.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 705,200,000 112,300,000 52,600,000 1,318,600,000 796,000,000 — 170,600,000
Dec 2024 1,013,600,000 -81,500,000 -190,600,000 1,389,700,000 906,900,000 — 58,700,000
Dec 2023 1,023,000,000 -201,500,000 -760,500,000 1,823,200,000 1,173,900,000 — -206,300,000
Dec 2022 1,076,100,000 -163,300,000 -211,600,000 3,166,300,000 1,778,600,000 — -34,100,000

TTM Snapshot

Revenues TTM
$1,046,900,000
NetIncome TTM
$-292,100,000
OpCashFlow TTM
$0
Assets (Latest)
$1,389,700,000
Forward EPS
$1.05

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $6.00 · spot: $5.18 · call volume: 171 · put volume: 142
Expected Move to 2026-09-18: ±$0.60 (11.58%) — implied range $4.58 – $5.78 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CAMP Camp4 Therapeutics Corp $271.09M $4.32 —
GLSI Greenwich LifeSciences, Inc. $258.04M $17.58 —
ADAG Adagene Inc. $257.68M $3.90 —
ALXO ALX ONCOLOGY HOLDINGS INC $275.17M $1.99 —
MGNX MACROGENICS INC $256.07M $4.02 —

News headlines (Yahoo Finance, 1h cache)

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
2026-08-12 22:13 · Yahoo
Emergent Biosolutions Q2 Earnings Call Highlights
2026-08-08 05:03 · Yahoo
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
2026-08-05 20:07 · Yahoo
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 20:01 · Yahoo
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
2026-06-29 13:13 · Yahoo
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
2026-06-04 12:02 · Yahoo
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
2026-05-28 20:01 · Yahoo
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
2026-05-20 20:43 · Yahoo
Emergent BioSolutions to Participate in Upcoming Investor Conferences
2026-05-20 11:30 · Yahoo
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
2026-05-18 12:59 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →